source
- Novartis CEO says shareholders remain supportive despite recent trial setbacksNovartis chief executive Vas Narasimhan told Fierce that, despite a series of recent clinical setbacks, most shareholders continue to back the company’s long-term strategy. The setbacks include th…
- BMS reports early Alzheimer’s psychosis data for Cobenfy showing reduced hallucinations but safety concerns remainAt the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, Bristol Myers Squibb presented early Phase 3 ADEPT data for KarXT, marketed as Cobenfy, in patients with Alzheimer’s disea…